publication . Other literature type . 2009

Liječenje multiple skleroze

Bošnjak-Pašić, Marija; Vidrih, Branka; Miškov, Snježana; Demarin, Vida;
Open Access English
  • Published: 01 Jan 2009 Journal: Acta clinica Croatica, volume 48, issue 3 (issn: 0353-9466, eissn: 1333-9451, Copyright policy)
  • Publisher: Sestre Milosrdnice University hospital and Institute of Clinical Medical Research
Abstract
Multipla skleroza (MS) je upalna autoimuna demijelinizacijska bolest središnjega živčanog sustava obilježena multifokalnom upalnom destrukcijom mijelina, oštećenjem aksona i gubitkom oligodendrocita. Bolest se odvija kroz dvije faze, upalnu i degenerativnu. Najčešći oblik bolesti, u otprilike 85% slučajeva je RRMS (relapsno-remitentni oblik). Liječenje MS dijeli se na liječenje akutne faze bolesti, prevenciju novih recidiva i progresije bolesti te simptomatsko liječenje. Posljednjih godina najviše promjena i novih lijekova u liječenju multiple skleroze rabi se u liječenju odnosno sprječavanju progresije bolesti te prevenciji recidiva bolesti. Neki od tih lijekov...
Subjects
free text keywords: Multiple sclerosis - therapy; Immunosuppressive agents - therapeutic use; Interferon, beta - therapeutic use, Multipla skleroza - terapija;Imunosupresivi - terapijska primjena; Interferon, beta - terapijska primjena
27 references, page 1 of 2

1. Choffion M. Mechanisms of action for treatments in multiple sclerosis. Biodrugs 2005;19:299-308

2. Isaacs A, Lindemann J. Virus interference. The interferon. Proc R Soc Lond (BioI) 1957;147;258-67

3. Iz rada struene grupe za lijekove Ministarstva zdravstva Republike Hrvatske. Pharmaca 1997;35:49-60

4. The IFNB MS Study Group.Interferon beta -Ib is effective in RRlVIS: clinical results of a multicentre, randomized, doubleblind, plecebo-controlled trial. Neurology 1993;43:665-61

5. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, DAmico R. Interferons in relapsing rmitting multiple sclerosis: a systematic review. Lancet 2003;361:545-52

6. ShariefMK. Dose and frequency of administration of interferon-beta affect its efficacy in multiple sclerosis. Clin drug Investig 2003;23:551-9

7. The PRISMS Study Group (Prevention of Relapses and Disability by Interferon Beta-la Subcutaneously in Multiple Sclerosis). Randomised double-blind placebo controlled study of interferon beta-la in relapsing/remitting multiple sclerosis . Lancet 1988;352:1498-504

8. Jacobs LD, Cookfair DL, Rudick RA. Results of a phase III trialof intramuscular recombinant beta interferon as treatmentof mul tiple sclerosis. Ann NeuroI1994;36:256 ???

9. Jacobs LD, Cookfair DL, Rudick RA. Intramuscular interferon-beta la for a disease progression in relapsing multiple sclerosis. Ann NeuroI1996;39:258-94

10. IFNB MS Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I MRI analysis results of a multicentre, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667

11. Kappos L. New aspects in the treatment of multiple sclerosis with interferon beta lb.]NeuroI2004;251(SuppI4):IV/l;DOI 10.1007/00415-004-1401-4

12. Durelli L. Is multiple sclerosis a disease that requires frequent beta interferon dosing? ] Neurol 2004;251(Suppl 4): IV/13­ IV/24;DOI10.1007/00415-004-1404-1

13. Comi G, Filippi M, BarkhofF, Durelli L, Edan G, Fernandez 0 et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357;1576-82 [OpenAIRE]

14. Galetta SL. The Controlled High Risk Avonex Multiple Sclerosis Trial (CHAlVIPS study). J Neuroophthalmol 2001;21;292-5

15. Kappos L, Polman CH , Freedman MS, Edan G, Hartung HP, Miller DH et al. Treatment with interferon beta-lb delays conversion t clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67;1242-9

27 references, page 1 of 2
Any information missing or wrong?Report an Issue